MyeloCelz exosomes

MyeloCelz exosomes are an investigational **exosome-based biologic** being developed by Creative Medical Technology Holdings for **type 1 diabetes**. The product consists of **cell-free extracellular vesicles secreted by cells from the MyeloCelz platform** and is intended to modulate autoimmune responses through **antigen-specific immune tolerance mechanisms** rather than direct cell replacement. Based on the provided context, the therapeutic concept is to use MyeloCelz-derived exosomes as an **immunotherapy for autoimmune disease**, particularly type 1 diabetes, and the associated patent filing also contemplates combination use with antibodies, cellular therapies, and small molecules that promote immunological tolerance. The precise molecular cargo, administration route, dosage form, and validated direct biological target have not been clearly disclosed in the provided material.

Other names

MyeloCelz exosomesantigen-specific exosomes derived from the MyeloCelz platform